IRINOTECAN BAXTER irinotecan hydrochloride trihydrate 40 mg/2 mL concentrated injection vial أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

irinotecan baxter irinotecan hydrochloride trihydrate 40 mg/2 ml concentrated injection vial

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: water for injections; lactic acid; sorbitol; hydrochloric acid; sodium hydroxide - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN BAXTER irinotecan hydrochloride trihydrate 300 mg/15 mL concentrated injection vial أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

irinotecan baxter irinotecan hydrochloride trihydrate 300 mg/15 ml concentrated injection vial

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 300 mg - injection, concentrated - excipient ingredients: lactic acid; sorbitol; hydrochloric acid; sodium hydroxide; water for injections - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN HYDROCHLORIDE 100 MG/5 ML- irinotecan hydrochloride injection الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

irinotecan hydrochloride 100 mg/5 ml- irinotecan hydrochloride injection

armas pharmaceuticals inc. - irinotecan hydrochloride (unii: 042laq1iis) (irinotecan - unii:7673326042) - • irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. - irinotecan hydrochloride injection is contraindicated in patients with a known hypersensitivity to the drug or its excipients. pregnancy category d [see warnings and precautions (5.9)] irinotecan hydrochloride can cause fetal harm when administered to a pregnant woman. radioactivity related to 14 c-irinotecan crosses the placenta of rats following intravenous administration of 10 mg/kg (which in separate studies produced an irinotecan cmax and auc about 3 and 0.5 times, respectively, the corresponding values in patients administered 125 mg/m2 ). intravenous administration of irinotecan 6 mg/kg/day to rats and rabbits during the period of organogenesis resulted in increased post-implantation loss and decreased numbers of live fetuses. in separate studies in rats, this dose produced an irinotecan cmax and auc of

IRINOTECAN HYDROCHLORIDE 40 MG/2 ML- irinotecan hydrochloride injection الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

irinotecan hydrochloride 40 mg/2 ml- irinotecan hydrochloride injection

armas pharmaceuticals inc. - irinotecan hydrochloride (unii: 042laq1iis) (irinotecan - unii:7673326042) - • irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. - irinotecan hydrochloride injection is contraindicated in patients with a known hypersensitivity to the drug or its excipients. pregnancy category d [see warnings and precautions (5.9)] irinotecan hydrochloride can cause fetal harm when administered to a pregnant woman. radioactivity related to 14 c-irinotecan crosses the placenta of rats following intravenous administration of 10 mg/kg (which in separate studies produced an irinotecan cmax and auc about 3 and 0.5 times, respectively, the corresponding values in patients administered 125 mg/m2 ). intravenous administration of irinotecan 6 mg/kg/day to rats and rabbits during the period of organogenesis resulted in increased post-implantation loss and decreased numbers of live fetuses. in separate studies in rats, this dose produced an irinotecan cmax and auc of

IRINOTECAN HYDROCHLORIDE- irinotecan hydrochloride injection, solution الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

irinotecan hydrochloride- irinotecan hydrochloride injection, solution

teva parenteral medicines, inc. - irinotecan hydrochloride (unii: 042laq1iis) (irinotecan - unii:7673326042) - - irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. - irinotecan hydrochloride injection is contraindicated in patients with a known hypersensitivity to the drug or its excipients. pregnancy category d [see warnings and precautions (5.9)] irinotecan hydrochloride injection can cause fetal harm when administered to a pregnant woman. radioactivity related to 14 c-irinotecan crosses the placenta of rats following intravenous administration of 10 mg/kg (which in separate studies produced an irinotecan cmax and auc about 3 and 0.5 times, respectively, the corresponding values in patients administered 125 mg/m2 ). intravenous administration of irinotecan 6 mg/kg/day to rats and rabbits during the period of organogenesis resulted in increased post-implantation loss and decreased numbers of live fetuses. in separate studies in rats, this dose produced an irinotecan cmax

IRINOTECAN HYDROCHLORIDE 40 MG/2 ML- irinotecan hydrochloride injection IRINOTECAN HYDROCHLORIDE 100 MG/ 5 ML- irinotecan hydro الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

irinotecan hydrochloride 40 mg/2 ml- irinotecan hydrochloride injection irinotecan hydrochloride 100 mg/ 5 ml- irinotecan hydro

bluepoint laboratories - irinotecan hydrochloride (unii: 042laq1iis) (irinotecan - unii:7673326042) - • irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. risk summary based on findings from animal studies and its mechanism of action, irinotecan hydrochloride can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . available postmarketing and published data reporting the use of irinotecan hydrochloride in pregnant women, are insufficient and confounded by the concomitant use of other cytotoxic drugs, to evaluate for any drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal studies, intravenous administration of irinotecan to rats and rabbits during the period of organogenesis resulted in embryofetal mortality and teratogenicity in pregnant animals at exposures lower than the human exposure based on auc at the clinical dose of 125 mg/m2 (see data ). advise pregnant women of t

MEDITAB IRINOTECAN irinotecan hydrochloride trihydrate 40 mg / 2 mL injection vial أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

meditab irinotecan irinotecan hydrochloride trihydrate 40 mg / 2 ml injection vial

cipla australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: sodium hydroxide; water for injections; lactic acid; sorbitol - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

MEDITAB IRINOTECAN irinotecan hydrochloride trihydrate 100 mg / 5 mL injection vial أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

meditab irinotecan irinotecan hydrochloride trihydrate 100 mg / 5 ml injection vial

cipla australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: sorbitol; lactic acid; water for injections; sodium hydroxide - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

DBL IRINOTECAN irinotecan 100mg/5mL (as hydrochloride) concentrated injection vial أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

dbl irinotecan irinotecan 100mg/5ml (as hydrochloride) concentrated injection vial

pfizer australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 100 mg - injection, concentrated - excipient ingredients: sorbitol; sodium hydroxide; water for injections; lactic acid; dilute hydrochloric acid - irinotecan injection is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan injection is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

DBL IRINOTECAN irinotecan 40mg/2mL (as hydrochloride) concentrated injection vial أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

dbl irinotecan irinotecan 40mg/2ml (as hydrochloride) concentrated injection vial

pfizer australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: sorbitol; water for injections; sodium hydroxide; lactic acid; dilute hydrochloric acid - irinotecan injection is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan injection is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.